Phase 3 Myasthenia Gravis Trial, Recruiting NCT06342544 Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Phase 3 Myasthenia Gravis Trial, Recruiting

NCT06342544
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with ocular myasthenia gravis (a condition affecting eye muscles) within the last 6 months
  • Your diagnosis was confirmed either by a specialist doctor observing typical symptoms, a positive blood test for certain antibodies, or specific nerve or medication tests (confirm with trial site)
  • You have had eye symptoms — such as drooping eyelids and/or double vision — for at least one month, and these symptoms affect only the eye area
  • Your symptoms have not spread beyond your eyes, as confirmed by standard assessments
  • You have not previously taken any immune-suppressing medications for this eye condition

Who may not be able to join:

  • You have a tumour of the thymus gland (thymoma)
  • You have abnormal pupil reactions not explained by a previous eye condition or surgery
  • You have eye movement problems caused by a thyroid-related eye condition
  • You have Graves' ophthalmopathy (a specific thyroid-related eye disease)
  • Your eye symptoms began more than one year before the trial screening date
  • You have a known allergy to any of the medications used in this trial, including rituximab, prednisone, azathioprine, or paracetamol, among others (confirm with trial site)
  • You currently have any type of infection
  • You have a seriously weakened immune system
  • You have severe heart failure or serious uncontrolled heart disease
  • You have severe liver disease
  • You have a psychotic condition that is not yet controlled by treatment
  • You have high uric acid levels and are taking certain medications to control it (such as allopurinol or febuxostat)
  • You are at risk of a specific type of glaucoma called angle-closure glaucoma
  • You have a prostate or urinary condition that could cause difficulty urinating
  • You need to receive a live vaccine during the study or within 6 months after finishing the trial treatment
  • You are a woman who could become pregnant and are not willing to use effective contraception during the trial and for at least 12 months afterwards
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +33148036852

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Registry
ClinicalTrials.gov
Start date
29 April 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

proportion of patients who progressed to generalized myasthenia within 2 years of follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov